COPT Defense Properties (NYSE:CDP) Issues Earnings Results

COPT Defense Properties (NYSE:CDP) issued its quarterly earnings results on Thursday. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02, Zacks reports. COPT Defense Properties had a return on equity of 9.71% and a net margin of 19.99%.The company had revenue of $197.36 million during the quarter, compared to the consensus estimate of $188.79 million. During the same period last year, the business posted $0.65 earnings per share. COPT Defense Properties’s revenue was up 7.6% on a year-over-year basis. COPT Defense Properties updated its FY 2026 guidance to 2.710-2.790 EPS and its Q1 2026 guidance to 0.670-0.690 EPS.

COPT Defense Properties Stock Performance

Shares of CDP traded up $0.90 during mid-day trading on Thursday, reaching $32.00. The company’s stock had a trading volume of 1,916,464 shares, compared to its average volume of 1,322,123. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 1.57. COPT Defense Properties has a 1-year low of $23.92 and a 1-year high of $32.14. The stock has a market cap of $3.62 billion, a P/E ratio of 24.06 and a beta of 0.86. The business has a 50-day simple moving average of $29.47 and a two-hundred day simple moving average of $29.03.

COPT Defense Properties Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Wednesday, December 31st were given a $0.305 dividend. This represents a $1.22 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date of this dividend was Wednesday, December 31st. COPT Defense Properties’s dividend payout ratio (DPR) is currently 91.73%.

Hedge Funds Weigh In On COPT Defense Properties

A number of hedge funds and other institutional investors have recently bought and sold shares of CDP. EverSource Wealth Advisors LLC increased its holdings in shares of COPT Defense Properties by 1,176.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,685 shares of the company’s stock valued at $46,000 after purchasing an additional 1,553 shares in the last quarter. Osaic Holdings Inc. grew its position in COPT Defense Properties by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,193 shares of the company’s stock valued at $88,000 after acquiring an additional 1,192 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in COPT Defense Properties during the 3rd quarter worth approximately $212,000. Quadrant Capital Group LLC purchased a new position in shares of COPT Defense Properties in the 3rd quarter valued at approximately $217,000. Finally, CIBC Bancorp USA Inc. acquired a new position in COPT Defense Properties during the 3rd quarter worth approximately $353,000.

COPT Defense Properties News Roundup

Here are the key news stories impacting COPT Defense Properties this week:

• Positive Sentiment: COPT reported quarterly FFO of $0.70/share, topping the Zacks consensus of $0.68 and rising from $0.65 a year ago — a direct metric REIT investors watch for valuation and dividend coverage. COPT Defense (CDP) Tops Q4 FFO and Revenue Estimates
• Positive Sentiment: The company established FY‑2026 FFOPS guidance of $2.71–$2.79 (Nareit and adjusted), well above the prior consensus (~$1.88), signaling stronger cash‑flow expectations for the year and supporting valuation for an income‑oriented stock. COPT Defense Establishes 2026 Guidance
• Positive Sentiment: COPT executed a full-building, ~148,000 sq. ft. lease with a top‑10 U.S. defense contractor at National Business Parkway, boosting leased percentage of its development pipeline (now ~86% leased) and de‑risking future cash flow. COPT Defense Executes Full Building Lease
• Neutral Sentiment: The company updated 1Q26 EPS guidance to $0.670–$0.690, roughly in line with the $0.670 consensus — suggesting near‑term GAAP earnings expectations are stable even as cash metrics improve. COPT Defense Establishes 2026 Guidance
• Negative Sentiment: COPT reported GAAP EPS of $0.33 for the quarter, missing the analyst consensus of $0.71 by $0.38 — a significant miss that could pressure near‑term sentiment despite the stronger cash‑flow outlook; revenue did beat expectations. COPT Defense Quarterly Earnings (MarketBeat)

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CDP. Jefferies Financial Group raised their price objective on COPT Defense Properties from $33.00 to $34.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Wells Fargo & Company raised their price target on shares of COPT Defense Properties from $30.00 to $33.00 and gave the stock an “overweight” rating in a report on Tuesday, November 25th. New Street Research set a $33.00 target price on COPT Defense Properties in a report on Monday, October 13th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of COPT Defense Properties in a research note on Wednesday, January 21st. Finally, Truist Financial upped their price objective on COPT Defense Properties from $30.00 to $31.00 and gave the company a “hold” rating in a research note on Monday, December 15th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

About COPT Defense Properties

COPT Defense Properties (NYSE: CDP) is a real estate investment trust organized to own, lease and manage healthcare and life science facilities serving the United States federal government, with a particular focus on Department of Defense and Veterans Affairs tenants. The company was formed in 2016 through a spin-off from Corporate Office Properties Trust, enabling it to concentrate exclusively on medical office buildings and specialized research facilities situated on or near military and federal research campuses.

The company’s portfolio comprises purpose-built, Class A medical office and outpatient specialty clinics, as well as life science laboratories.